Enstar Group Limited Reports Second Quarter 2024 Results
July 29, 2024 07:15 ET
|
Enstar Group Limited
Enstar to be Acquired by Sixth Street-led Consortium for $5.1 BillionNet Income Attributable to Enstar Ordinary Shareholders of $126 Million; Return on Equity of 2.5% Primarily Driven by Positive...
Steakholder Foods® Foods Announces Submission of Its 2024 UN Global Compact Communication on Progress
July 29, 2024 07:11 ET
|
STEAKHOLDER FOODS LTD.
Report Details Company’s Dedication to Sustainable Business Practices and Ethical Standards Rehovot, Israel, July 29, 2024 (GLOBE NEWSWIRE) -- Steakholder Foods Ltd. (Nasdaq: STKH), a...
Enstar to be Acquired by Sixth Street for $5.1 Billion
July 29, 2024 07:07 ET
|
Enstar Group Limited
Enstar shareholders to receive $338.00 per share in cash Strong alignment between Enstar and Sixth Street to ensure continuity of Enstar strategy HAMILTON, Bermuda, July 29, 2024 (GLOBE NEWSWIRE)...
Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results
July 29, 2024 07:02 ET
|
Ocugen
MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
LuxUrban Hotels Announces Agreement in Principle to Issue Up to $5.0 Million Senior Notes Due 2027
July 29, 2024 07:01 ET
|
LuxUrban Hotels
MIAMI, July 29, 2024 (GLOBE NEWSWIRE) -- LuxUrban Hotels Inc. (“LuxUrban” or the “Company”) (Nasdaq: LUXH), which secures long-term operating rights for entire hotels through Master Lease Agreements...
Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients
July 29, 2024 07:00 ET
|
Cognition Therapeutics, Inc.
- CT1812 Treatment Showed ~40% Mean Improvement in Cognitive Measures vs Placebo -- Consistent Positive Changes Across Cognitive and Functional Measures -- Favorable Safety Profile with Most...
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease
July 29, 2024 07:00 ET
|
Acumen Pharmaceuticals, Inc.
NEWTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid...
Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain
July 29, 2024 07:00 ET
|
Rapport Therapeutics, Inc.
BOSTON and SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational...
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
July 29, 2024 07:00 ET
|
Eledon Pharmaceuticals, Inc.
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
ECARX Announces Board Change
July 29, 2024 07:00 ET
|
ECARX LIMITED
SHANGHAI, July 29, 2024 (GLOBE NEWSWIRE) -- ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility tech provider, today announced the appointment of Mr. Tao Li as a director...